Nonalcoholic Fatty Liver
Metabolic Diseases
1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
City TherapeuticsMA - Cambridge
1 program1
Elobixibat 10mg + cholestyramine powder 9gPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
City TherapeuticsElobixibat 10mg + cholestyramine powder 9g
Clinical Trials (1)
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
Start: Jan 2020Est. completion: Sep 2021
Phase 2Completed
Related Jobs in Metabolic Diseases
Principal Product Engineer
Medtronic
North Haven, Connecticut, United States of America
Yesterday
$120K - $180K/yr
Obesity Commercial Lead (Pre-Launch), ICO
Pfizer
United Kingdom - Walton Oaks; Europe - Any Pfizer Site
Yesterday
Vice President, Head of Financial Planning and Analysis
NewAmsterdam Pharma
Remote
Yesterday
Senior Product Manager - Body Composition
GE HealthCare
Remote
2d ago
$150K - $224K/yr
Medical Science Liaison - Obesity - MN, IA, WI
Amgen
Minnesota - Minneapolis, US
2d ago
Senior Medical Science Liaison - Obesity - CO, NE, AZ, NM, UT
Amgen
Colorado - Denver, US
2d ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space